Amgen Plummets 0.72% as $470M Volume Ranks 263rd Amid Patent Expirations and Biosimilar Competition Before Earnings

Amgen (AMGN) fell 0.72% on July 30, 2025, with a trading volume of $0.47 billion, ranking 263rd in the market. The stock is set to report Q2 earnings on August 5, with analysts projecting $5.25 per share and $8.86 billion in revenue. Key drivers include strong volume growth for Evenity, Repatha, and Blincyto, though pricing pressures from rebates and biosimilars may weigh on sales. Patent expirations for Prolia and Xgeva in 2025 and biosimilar launches by Sandoz could erode revenue, while newer drugs like Tezspire and Tavneos may offset declines. Higher R&D costs and competitive pressures in oncology biosimilars could further impact margins.

Investors are monitoring Amgen’s ability to balance volume gains with pricing challenges. Recent biosimilar launches, including Wezlana (Stelara) and Pavblu (Eylea), face sales volatility, while Bekemv (Soliris) enters the market in Q2 2025. The company’s pipeline, including MariTide for obesity, remains a focal point for long-term growth. Despite four consecutive quarters of earnings beats, analysts caution that patent cliffs and biosimilar competition could test resilience in the second half of 2025.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to July 30, 2025, outperforming the benchmark’s 29.18% by 137.53%. This approach achieved a 31.89% CAGR, highlighting the effectiveness of volume-driven short-term positioning across high-liquidity stocks like PTC and Adobe. The results underscore the potential of leveraging market sentiment and liquidity for capital appreciation, though Amgen’s specific performance remains subject to its unique earnings and product dynamics.